[조사자료] 글로벌 출혈성 질환 시장 (2023-2032) : 혈우병 A, 혈우병 B, 폰빌레브란트병, 기타

■ 영문 제목 : Bleeding Disorders Market By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others), By Treatment Type (Factor Replacement Therapy, Drug Therapy), By Distribution Channel (Hospital Pharmacies, Drug stores and retail pharmacies, Online pharmacies): Global Opportunity Analysis and Industry Forecast, 2023-2032
	■ 상품코드 : ALD23SEP133 ■ 조사/발행회사 : Allied Market Research ■ 발행일 : 2023년 5월 ■ 페이지수 : 458 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 ■ 조사대상 지역 : 세계

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User	USD5,730 ⇒환산￦7,735,500	견적의뢰/주문/질문
5 User	USD6,450 ⇒환산￦8,707,500	견적의뢰/주문/질문
Enterprise User	USD9,600 ⇒환산￦12,960,000	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

글로벌 출혈성 질환 시장은 2022년에 137억 8,966만 달러로 평가되었으며 2032년에는 259억 7,482만 달러에 달할 것으로 예상되며, 2023년부터 2032년까지 6.6%의 연평균 성장률을 보일 것으로 예상됩니다. 출혈성 질환는 혈액 내 특정 응고 인자의 결핍 또는 기능 장애로 인한 비정상적인 출혈을 특징으로 하는 질환 그룹입니다. 일반적으로 사람이 부상이나 상처를 입으면 신체는 출혈을 막기 위해 혈전을 형성합니다. 그러나 출혈성 질환가 있는 사람은 이 과정이 손상되거나 부재하여 비정상적이거나 과도한 출혈을 일으킬 수 있습니다. 혈우병은 가장 잘 알려져 있고 흔한 출혈성 질환로, 대부분 남성에게 영향을 미치며 생명을 위협하는 심각한 출혈을 일으킬 수 있습니다. 폰 빌레브란트 병은 남성과 여성 모두에게 영향을 미치는 또 다른 흔한 출혈성 질환로 부상이나 수술 후 장기간 출혈을 유발할 수 있습니다.

출혈성 질환 시장의 성장을 이끄는 주요 요인으로는 출혈성 질환 치료의 급속한 발전, A형 혈우병, B형 혈우병 및 기타 출혈성 질환를 앓고 있는 환자 수 증가 등이 있습니다. 예를 들어, 2022년 미국 질병통제예방센터(CDC)에 따르면 미국에서는 33,000명의 남성이 출혈성 질환를 앓고 있습니다.

또한 혈우병 관리를 위한 유리한 정부 이니셔티브, 출혈성 질환 치료에 대한 인식 프로그램 수 증가, 항 혈우병 약물 개발을위한 임상 시험 수 증가는 출혈성 질환 시장의 성장을 촉진합니다. 또한 대상 인구의 증가, 진단율의 증가, 혈우병 예방 치료의 사용 급증은 시장 성장을 촉진합니다.
그러나 혈우병 치료의 높은 비용과 혈장 유래 제품과 관련된 심각한 부작용은 출혈성 질환 시장의 성장을 제한 할 것으로 예상됩니다. 반면, 의료비 지출의 급증과 개발도상국의 혈우병 치료 옵션에 대한 미충족 의료 수요는 향후 글로벌 시장 확대에 막대한 기회를 창출 할 것으로 예상됩니다.

출혈성 질환 시장은 질병 유형, 치료 유형, 유통 채널 및 지역을 기준으로 세분화됩니다. 질병 유형에 따라 시장은 혈우병 A, 혈우병 B, 폰 빌레브란트 병 및 기타로 분류됩니다. 치료 유형에 따라 시장은 인자 대체 요법과 약물 요법 (데스 모 프레신, 항 섬유소 용해제, 섬유소 실란트)으로 분류됩니다. 인자 대체 요법 부문은 혈장 유래 응고 인자 농축액과 재조합 응고 인자 농축액으로 더 세분화됩니다. 유통 채널을 기준으로 출혈성 질환 시장은 병원 약국, 약국 및 소매 약국, 온라인 약국으로 세분화됩니다. 지역을 기준으로 시장은 북미 (미국, 캐나다 및 멕시코), 유럽 (독일, 프랑스, 영국, 이탈리아, 스페인 및 기타 유럽 지역), 아시아 태평양 (중국, 일본, 호주, 인도, 한국 및 기타 아시아 태평양) 및 중남미/중동/아프리카 (브라질, 남아프리카 공화국, 사우디 아라비아 및 기타 중남미/중동/아프리카)에서 분석됩니다.

이 보고서에서 프로파일링된 주요 기업으로는 Bayer AG, CSL Ltd. (CSL Behring), F. Hoffmann-La Roche AG, Grifols, S.A., Medexus Pharma, Inc., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., SANOFI CORPORATION, and Takeda Pharmaceutical Company Limited. 등이 있습니다. 시장의 주요 업체들은 출혈성 질환 시장의 제품 포트폴리오를 개선하기 위한 주요 개발 전략으로 투자, 파트너십 및 제품 승인을 채택했습니다.

이해 관계자를 위한 주요 이점
이 보고서는 2022년부터 2032년까지 출혈성 질환 시장 분석의 시장 부문, 현재 동향, 추정치 및 역학에 대한 정량적 분석을 제공하여 일반적인 출혈성 질환 시장 기회를 식별합니다.
시장 조사는 주요 동인, 제약 및 기회와 관련된 정보와 함께 제공됩니다.
포터의 다섯 가지 경쟁 요인 분석은 이해 관계자가 이익 지향적인 비즈니스 결정을 내리고 공급 업체-구매자 네트워크를 강화할 수 있도록 구매자와 공급 업체의 잠재력을 강조합니다.
출혈성 질환 시장 세분화에 대한 심층 분석은 일반적인 시장 기회를 결정하는 데 도움이 됩니다.
각 지역의 주요 국가는 글로벌 시장에 대한 매출 기여도에 따라 매핑됩니다.
시장 플레이어 포지셔닝은 벤치마킹을 용이하게하고 시장 플레이어의 현재 위치에 대한 명확한 이해를 제공합니다.
이 보고서에는 지역 및 글로벌 출혈성 질환 시장 동향, 주요 업체, 시장 부문, 응용 분야 및 시장 성장 전략에 대한 분석이 포함되어 있습니다.

주요 시장 부문
질병 유형별
혈우병 A형
혈우병 B
폰 빌레브란트 병
기타

치료 유형별
응고인자 대체 요법
유형
재조합 응고인자 농축액
혈장 유래 응고인자 농축액
약물 요법

유통 채널별
병원 약국
약국 및 소매 약국
온라인 약국

지역별
북미
미국
캐나다
멕시코
유럽
독일
프랑스
영국
이탈리아
스페인
기타 유럽 지역
아시아 태평양
일본
중국
호주
인도
한국
기타 아시아 태평양 지역
중남미/중동/아프리카
브라질
사우디 아라비아
남아프리카 공화국
기타 중동 및 아프리카 지역

주요 기업
○ Medexus Pharma, Inc.
○ Bayer AG
○ Novo Nordisk A/S
○ Grifols, S.A.
○ Octapharma AG
○ Takeda Pharmaceutical Company Limited
○ CSL Limited
○ Pfizer Inc.
○ Sanofi
○ F. Hoffmann-La Roche Ltd.

■ 보고서 개요

CHAPTER 1 : 소개
CHAPTER 2 : 개요
CHAPTER 3 : 시장 동향
CHAPTER 4 : 출혈성 질환 시장, 질병 유형별
CHAPTER 5 : 출혈성 질환 시장, 치료 유형별
CHAPTER 6 : 출혈성 질환 시장, 유통 채널별
CHAPTER 7 : 출혈성 질환 시장, 지역별
CHAPTER 8 : 경쟁 현황
CHAPTER 9 : 기업 정보

■ 보고서 목차

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of hemophilia
3.4.1.2. Technological advancements in treatment of hemophilia
3.4.1.3. Favorable government initiatives for hemophilia management

3.4.2. Restraints
3.4.2.1. High cost of bleeding disorders treatments

3.4.3. Opportunities
3.4.3.1. Rise in awareness about bleeding disorders in developing countries

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: BLEEDING DISORDERS MARKET, BY DISEASE TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Hemophilia A
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Hemophilia B
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Von Willebrand Disease
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Others
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
CHAPTER 5: BLEEDING DISORDERS MARKET, BY TREATMENT TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Factor Replacement Therapy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.2.4. Factor Replacement Therapy Bleeding Disorders Market by Type
5.3. Drug Therapy
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drug stores and retail pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: BLEEDING DISORDERS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Disease Type
7.2.3. Market size and forecast, by Treatment Type
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Disease Type
7.2.5.1.3. Market size and forecast, by Treatment Type
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Disease Type
7.2.5.2.3. Market size and forecast, by Treatment Type
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Disease Type
7.2.5.3.3. Market size and forecast, by Treatment Type
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Disease Type
7.3.3. Market size and forecast, by Treatment Type
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Disease Type
7.3.5.1.3. Market size and forecast, by Treatment Type
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Disease Type
7.3.5.2.3. Market size and forecast, by Treatment Type
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Disease Type
7.3.5.3.3. Market size and forecast, by Treatment Type
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Disease Type
7.3.5.4.3. Market size and forecast, by Treatment Type
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Disease Type
7.3.5.5.3. Market size and forecast, by Treatment Type
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Disease Type
7.3.5.6.3. Market size and forecast, by Treatment Type
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Disease Type
7.4.3. Market size and forecast, by Treatment Type
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Disease Type
7.4.5.1.3. Market size and forecast, by Treatment Type
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Disease Type
7.4.5.2.3. Market size and forecast, by Treatment Type
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Disease Type
7.4.5.3.3. Market size and forecast, by Treatment Type
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Disease Type
7.4.5.4.3. Market size and forecast, by Treatment Type
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Disease Type
7.4.5.5.3. Market size and forecast, by Treatment Type
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Disease Type
7.4.5.6.3. Market size and forecast, by Treatment Type
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Disease Type
7.5.3. Market size and forecast, by Treatment Type
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Disease Type
7.5.5.1.3. Market size and forecast, by Treatment Type
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Disease Type
7.5.5.2.3. Market size and forecast, by Treatment Type
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Disease Type
7.5.5.3.3. Market size and forecast, by Treatment Type
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Disease Type
7.5.5.4.3. Market size and forecast, by Treatment Type
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Pfizer Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Novo Nordisk A/S
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Bayer AG
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Octapharma AG
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Sanofi
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Medexus Pharma, Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Grifols, S.A.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. F. Hoffmann-La Roche Ltd.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. CSL Limited
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Takeda Pharmaceutical Company Limited
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments

LIST OF TABLES
TABLE 01. GLOBAL BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 02. BLEEDING DISORDERS MARKET FOR HEMOPHILIA A, BY REGION, 2022-2032 ($MILLION)
TABLE 03. BLEEDING DISORDERS MARKET FOR HEMOPHILIA B, BY REGION, 2022-2032 ($MILLION)
TABLE 04. BLEEDING DISORDERS MARKET FOR VON WILLEBRAND DISEASE, BY REGION, 2022-2032 ($MILLION)
TABLE 05. BLEEDING DISORDERS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GLOBAL BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 07. BLEEDING DISORDERS MARKET FOR FACTOR REPLACEMENT THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL FACTOR REPLACEMENT THERAPY BLEEDING DISORDERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 09. BLEEDING DISORDERS MARKET FOR DRUG THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 11. BLEEDING DISORDERS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 12. BLEEDING DISORDERS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. BLEEDING DISORDERS MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 14. BLEEDING DISORDERS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 19. U.S. BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 20. U.S. BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 21. U.S. BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 22. CANADA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 23. CANADA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 24. CANADA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 25. MEXICO BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 26. MEXICO BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 27. MEXICO BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. EUROPE BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 29. EUROPE BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 30. EUROPE BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 31. EUROPE BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 32. GERMANY BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 33. GERMANY BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 34. GERMANY BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 35. FRANCE BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 36. FRANCE BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 37. FRANCE BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. UK BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 39. UK BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 40. UK BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. ITALY BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 42. ITALY BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 43. ITALY BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 44. SPAIN BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 45. SPAIN BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 46. SPAIN BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 54. JAPAN BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 55. JAPAN BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 56. JAPAN BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 57. CHINA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 58. CHINA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 59. CHINA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 63. INDIA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 64. INDIA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 65. INDIA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 72. LAMEA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 73. LAMEA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 74. LAMEA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 75. LAMEA BLEEDING DISORDERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 76. BRAZIL BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 77. BRAZIL BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 78. BRAZIL BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 81. SAUDI ARABIA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA BLEEDING DISORDERS MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA BLEEDING DISORDERS MARKET, BY TREATMENT TYPE, 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA BLEEDING DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 88. PFIZER INC.: KEY EXECUTIVES
TABLE 89. PFIZER INC.: COMPANY SNAPSHOT
TABLE 90. PFIZER INC.: PRODUCT SEGMENTS
TABLE 91. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 92. PFIZER INC.: KEY STRATERGIES
TABLE 93. NOVO NORDISK A/S: KEY EXECUTIVES
TABLE 94. NOVO NORDISK A/S: COMPANY SNAPSHOT
TABLE 95. NOVO NORDISK A/S: PRODUCT SEGMENTS
TABLE 96. NOVO NORDISK A/S: PRODUCT PORTFOLIO
TABLE 97. NOVO NORDISK A/S: KEY STRATERGIES
TABLE 98. BAYER AG: KEY EXECUTIVES
TABLE 99. BAYER AG: COMPANY SNAPSHOT
TABLE 100. BAYER AG: PRODUCT SEGMENTS
TABLE 101. BAYER AG: PRODUCT PORTFOLIO
TABLE 102. OCTAPHARMA AG: KEY EXECUTIVES
TABLE 103. OCTAPHARMA AG: COMPANY SNAPSHOT
TABLE 104. OCTAPHARMA AG: PRODUCT SEGMENTS
TABLE 105. OCTAPHARMA AG: PRODUCT PORTFOLIO
TABLE 106. OCTAPHARMA AG: KEY STRATERGIES
TABLE 107. SANOFI: KEY EXECUTIVES
TABLE 108. SANOFI: COMPANY SNAPSHOT
TABLE 109. SANOFI: PRODUCT SEGMENTS
TABLE 110. SANOFI: PRODUCT PORTFOLIO
TABLE 111. SANOFI: KEY STRATERGIES
TABLE 112. MEDEXUS PHARMA, INC.: KEY EXECUTIVES
TABLE 113. MEDEXUS PHARMA, INC.: COMPANY SNAPSHOT
TABLE 114. MEDEXUS PHARMA, INC.: PRODUCT SEGMENTS
TABLE 115. MEDEXUS PHARMA, INC.: PRODUCT PORTFOLIO
TABLE 116. MEDEXUS PHARMA, INC.: KEY STRATERGIES
TABLE 117. GRIFOLS, S.A.: KEY EXECUTIVES
TABLE 118. GRIFOLS, S.A.: COMPANY SNAPSHOT
TABLE 119. GRIFOLS, S.A.: PRODUCT SEGMENTS
TABLE 120. GRIFOLS, S.A.: PRODUCT PORTFOLIO
TABLE 121. GRIFOLS, S.A.: KEY STRATERGIES
TABLE 122. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 123. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 124. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 125. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 126. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 127. CSL LIMITED: KEY EXECUTIVES
TABLE 128. CSL LIMITED: COMPANY SNAPSHOT
TABLE 129. CSL LIMITED: PRODUCT SEGMENTS
TABLE 130. CSL LIMITED: PRODUCT PORTFOLIO
TABLE 131. CSL LIMITED: KEY STRATERGIES
TABLE 132. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
TABLE 133. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
TABLE 134. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS
TABLE 135. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
TABLE 136. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES

※본 조사보고서 [글로벌 출혈성 질환 시장 (2023-2032) : 혈우병 A, 혈우병 B, 폰빌레브란트병, 기타] (코드 : ALD23SEP133) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [글로벌 출혈성 질환 시장 (2023-2032) : 혈우병 A, 혈우병 B, 폰빌레브란트병, 기타] 에 대해서 E메일 문의는 여기를 클릭하세요.

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!

[이하, 관련 보고서 소개]

글로벌 림프종 치료제 시장 (2023-2032) : 호지킨 림프종, 비호지킨 림프종
ALD23SEP105 / Allied Market Research / 2023년 4월 / 세계의 림프종 치료제 시장은 2022년 156억 9,145만 달러로 평가되며 2023년부터 2032년까지 8.4%의 연평균 성장률을 보이며 2032년에는 352억 7,450만 달러에 달할 것으로 예상됩니다. 림프종은 감염 및 기타 질병과 싸우는 데 도움이...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 림프종 치료제 시장, 질병 유형별 CHAPTER 5 : 림프종 치료제 시장, 치료 유형별 CHAPTER 6 : 림프종 치료제 시장, 투여 경로별 CHAPTER 7 : 림프종 치료제 시장, 유통 채널별 CHAPTER 8 : 림프종 치료제...

글로벌 노인 황반 변성 (AMD) 치료제 시장 (2023-2032) : 애플리버셉트, 라니비주맙, 기타
ALD23SEP135 / Allied Market Research / 2023년 5월 / 글로벌 노인 황반 변성 (AMD) 치료제 시장 규모는 2022년에 94억 달러였으며 2023년부터 2032년까지 연평균 5%씩 성장하여 2032년에는 154억 달러에 달할 것으로 예상됩니다. 노인 황반 변성 (AMD)은 전 세계 수백만 명의...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 노인 황반 변성 (AMD) 치료제 시장, 약물 유형별 CHAPTER 5 : 노인 황반 변성 (AMD) 치료제 시장, 질병 유형별 CHAPTER 6 : 노인 황반 변성 (AMD) 치료제 시장, 유통 채널별 CHAPTER 7 : 노인...

글로벌 만성 신장질환 (CKD) 치료 시장 (2023-2032) : 의약품, 투석
ALD23SEP152 / Allied Market Research / 2023년 5월 / 글로벌 만성 신장질환 (CKD) 치료 시장은 2022년 3,198억 2,276만 달러 규모였으며 2023년부터 2032년까지 4%의 연평균 성장률을 보이며 2032년에는 4,790억 2,270만 달러에 달할 것으로 예상됩니다. 만성 신장질환(CKD) 치료는 신장 손상 및...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 만성 신장질환(CKD) 치료제 시장, 치료법별 CHAPTER 5 : 만성 신장질환(CKD) 치료제 시장, 최종 용도별 CHAPTER 6 : 만성 신장질환(CKD) 치료제 시장, 지역별 CHAPTER 7 : 경쟁 현황 CHAPTER 8 : 기업 정보...

글로벌 근위축성 측색 경화증 (ALS) 치료제 시장 (2023-2032) : 리루졸, 에다라본, 기타
ALD23SEP115 / Allied Market Research / 2023년 4월 / 글로벌 근위축성 측색 경화증 (ALS) 치료제 시장은 2022년 6억 6,225만 달러에 달했으며 2023년부터 2032년까지 4.6%의 연평균 성장률을 보이며 2032년에는 10억 3,894만 달러에 달할 것으로 예상됩니다. 루게릭병으로도 알려진 근위축성 측색 경화증...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 근위축성 측색 경화증 (ALS) 치료제 시장, 약품별 CHAPTER 5 : 근위축성 측색 경화증 (ALS) 치료제 시장, 유형별 CHAPTER 6 : 근위축성 측색 경화증 (ALS) 치료제 시장, 유통 채널별 CHAPTER 7 : 근위축성 측색 경화증...

글로벌 승모판막 질환 치료제 시장 (2023-2032) : 베타 차단제, 이뇨제, 항응고제, 기타
ALD23SEP151 / Allied Market Research / 2023년 5월 / 글로벌 승모판막 질환 치료제 시장은 2022년 6억 7,774만 달러에 달했으며 2023년부터 2032년까지 2.8%의 연평균 성장률을 보이며 2032년에는 8억 3,344만 달러에 달할 것으로 예상됩니다. 승모판막 질환은 심장의 좌심방과 좌심실 사이에 위치한...CHAPTER 1 : 소개 CHAPTER 2 : 개요 CHAPTER 3 : 시장 동향 CHAPTER 4 : 승모판막 질환 치료제 시장, 약품 종류별 CHAPTER 5 : 승모판막 질환 치료제 시장, 연령대별 CHAPTER 6 : 승모판막 질환 치료제 시장, 유통 채널별 CHAPTER 7 : 승모판막 질환 치료제 시장, 지역별 CHAPTER 8 :...